Article in Neurology(R) neuroimmunology & neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
41 authors.
Sara CartaNeurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Italy.ORCID 0000-0001-5248-456X
Riccardo TiberiNeurological Clinic, Experimental and Clinical Medicine Department, Marche Polytechnic University, Ancona, Italy.
Nicola De RossiMultiple Sclerosis Center, ASST Spedali Civili di Brescia - P.O. Montichiari, Montichiari, Italy.
Giorgia Teresa ManiscalcoNeurological Clinic and Stroke Unit and Multiple Sclerosis Center "A. Cardarelli" Hospital, Napoli, Italy.ORCID 0000-0002-0679-9939
Antonio LottiDepartment of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Italy.ORCID 0000-0001-8121-2627
Alessandro MarzialiDepartment of Medicine (DMED), University of Udine, Italy.ORCID 0009-0006-2597-7186
Arianna SartoriDepartment of Medicine, Surgery and Health Sciences, Neurology Unit, Cattinara University Hospital ASUGI, University of Trieste, Italy.ORCID 0000-0002-4518-518X
Anna FaveroDepartment of Medicine, Surgery and Health Sciences, Neurology Unit, Cattinara University Hospital ASUGI, University of Trieste, Italy.ORCID 0009-0008-2934-6503
Francesca RossiNeurology Unit, Mater Salutis Hospital, Legnago, Verona, Italy.ORCID 0009-0006-6233-979X
Alessandro DinotoNeurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Italy.ORCID 0000-0002-3249-4792
Milena TrentinagliaNeurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Italy.ORCID 0009-0006-2596-908X
Vanessa ChiodegaNeurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Italy.ORCID 0000-0001-5636-0804
Federica BosoNeurology Unit, Trento Hospital, Azienda Provinciale per i Servizi Sanitari (APSS) di Trento, Italy.ORCID 0000-0002-9293-9431
Stefano de BiaseNeurology Unit, Ospedale Dell'Angelo AULSS 3 Serenissima, Venice Mestre, Italy.ORCID 0000-0001-7328-4401
Francesca CaleriDepartment of Neurology, MS Center, F. Tappeiner Hospital, Merano, Italy.ORCID 0000-0002-1617-9258
Riccardo OrlandiNeurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Italy.ORCID 0000-0003-3375-4098
Enis GusoDepartment of Continuity of Care and Frailty, Neurology Unit, ASST-Spedali Civili, Brescia, Italy.
Irene VolonghiDepartment of Continuity of Care and Frailty, Neurology Unit, ASST-Spedali Civili, Brescia, Italy.ORCID 0000-0002-6864-1475
Margherita NosadiniPaediatric Neurology and Neurophysiology Unit, Department of Women's and Children's Health, University Hospital of Padova. Neuroimmunology Group, Paediatric Research Institute "Città della Speranza", Padova, Italy.ORCID 0000-0002-6395-7614
Stefano SartoriPaediatric Neurology and Neurophysiology Unit, Department of Women's and Children's Health, University Hospital of Padova. Neuroimmunology Group, Paediatric Research Institute "Città della Speranza", Padova, Italy.ORCID 0000-0002-0012-6848
Pasqualina PalmieriChild Neuropsychiatry Unit, Department of Children and Maternal Health, AOUI Verona, Full Member of European Reference Network EpiCARE, Italy.
Alberto CossuChild Neuropsychiatry Unit, Department of Children and Maternal Health, AOUI Verona, Full Member of European Reference Network EpiCARE, Italy.ORCID 0000-0001-6945-6151
Giovanna De LucaNeurology Unit, Multiple Sclerosis Centre, SS Annunziata University Hospital, Chieti, Italy.ORCID 0000-0002-7693-2256
Marco ZoccaratoNeurology Unit O.S.A., Azienda Ospedale-Università di Padova, Italy.ORCID 0000-0002-0182-6555
Anna de MauroDepartment of Medicine, Surgery and Neuroscience, University of Siena, Italy; and.ORCID 0009-0009-5694-5226
Luca MassacesiDepartment of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Italy.ORCID 0000-0001-5083-372X
Rosa CorteseDepartment of Medicine, Surgery and Neuroscience, University of Siena, Italy; and.ORCID 0000-0002-9803-7914
Alberto GajofattoNeurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Italy.ORCID 0000-0001-6539-0458
Patrizia RossiNeurology Unit, AULSS7 Pedemontana, St Bassiano Hospital, Bassano del Grappa, Vicenza, Italy.ORCID 0009-0001-8653-1747
Elia SechiNeurology Unit, Department of Medicine, Surgery and Pharmacy, University Hospital of Sassari, Italy.ORCID 0000-0003-4698-663X
Valentina DamatoDepartment of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Italy.ORCID 0000-0003-1740-4522
Sara MariottoNeurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Italy.ORCID 0000-0002-7806-3103
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
objectivesA score evaluating age at onset, sex, clinical phenotype, and treatment received (MOG-AR) has been proposed to identify MOGAD patients at high relapse risk. The aim of this study was to validate the MOG-AR score in a multicenter cohort and to assess other variables potentially associated with relapses.
methodsMOGAD patients were retrospectively enrolled from 24 centers. The MOG-AR score was applied and 4 categories of relapse risk were identified (grade I: lowest risk; grade IV: highest risk), accordingly. The association of MOG-AR score and additional variables with a relapsing course were then explored.
resultsOf 190 included patients, the median age at onset was 37 [IQR 23-51] years and 107 (56%) were female. A total of 78 patients (41%) experienced a relapse during a median of 43.6 months [24.8-75.4]. Using the proposed cutoff of 9, the MOG-AR score had a sensitivity of 53.9% [95% CI 55.6-73.9] and a specificity of 65.18% [95% CI 55.60-73.93]; area under the curve: 0.64 (95% CI 0.57-0.72). Among additional investigated factors, only immunosuppressive treatment after the presenting MOGAD attack was associated with a lower relapse risk. DISCUSSION: MOG-AR score failed to accurately predict a relapsing disease course. Only immunosuppressive treatment after the first event was significantly associated with a lower relapse risk.
Indexed as
AdultAge of OnsetFemaleHumansMaleMiddle AgedRecurrenceRetrospective StudiesYoung Adult
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Validation of the MOG-AR Score: A Retrospective Multicenter Study. · full record | OpenQuestion